Poutanen Tuija, Tikanoja Tero, Jääskeläinen Pertti, Jokinen Eero, Silvast Annuli, Laakso Markku, Kuusisto Johanna
Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Am Heart J. 2006 Mar;151(3):725.e1-725.e9. doi: 10.1016/j.ahj.2005.12.005.
We investigated the presence of left ventricular hypertrophy (LVH) and features of diastolic dysfunction in genotype-confirmed children from families with hypertrophic cardiomyopathy (HCM) and healthy control children.
In subjects with HCM-causing mutations, LVH usually does not evolve until adolescence. Diastolic dysfunction has not been systematically evaluated in children carrying HCM-causing mutations.
All children (aged 1.5-16.7 years) from 14 HCM families with identified disease-causing mutations (the Arg719Trp mutation in the beta-myosin heavy chain gene [MYH7], the Asp175Asn mutation in the alpha-tropomyosin gene [TPM1], the Gln1061X mutation in the myosin-binding protein C gene [MYBPC3], and the IVS5-2A-->C mutation in the MYBPC3 gene) and 53 matched control children were examined with electrocardiography and 2- and 3-dimensional echocardiography (2DE and 3DE). Natriuretic peptides were measured in children from HCM families and 67 control children.
Of 53 children from HCM families, 27 (51%) had a disease-causing mutation (G+). G+ children had slightly thicker septum on 2DE compared with the control children (P = .004), but only 3 (11%) of 27 G+ children exceeded the 95th percentile values of the body surface area-adjusted maximal LV thickness of healthy children (the major echocardiographic criterion for HCM). However, prolonged isovolumetric relaxation time, increased left atrial volume on 3DE, or increased levels of NT-proANP, all features suggestive of diastolic dysfunction, were found in 14 (52%) of 27 G+ children.
In children with HCM-causing mutations, signs of diastolic dysfunction are found in about half of the cases, as LVH is present only in small percentage of these children.
我们调查了肥厚型心肌病(HCM)家族中基因确诊儿童及健康对照儿童左心室肥厚(LVH)的存在情况和舒张功能障碍的特征。
在携带HCM致病突变的受试者中,LVH通常直到青春期才会发展。携带HCM致病突变的儿童的舒张功能障碍尚未得到系统评估。
对来自14个已鉴定出致病突变的HCM家族(β-肌球蛋白重链基因[MYH7]中的Arg719Trp突变、α-原肌球蛋白基因[TPM1]中的Asp175Asn突变、肌球蛋白结合蛋白C基因[MYBPC3]中的Gln1061X突变以及MYBPC3基因中的IVS5-2A→C突变)的所有儿童(年龄1.5 - 16.7岁)和53名匹配的对照儿童进行了心电图检查以及二维和三维超声心动图(2DE和3DE)检查。对HCM家族的儿童和67名对照儿童测量了利钠肽。
在53名来自HCM家族的儿童中,27名(51%)携带致病突变(G+)。与对照儿童相比,G+儿童在2DE上的室间隔略厚(P = 0.004),但27名G+儿童中只有3名(11%)超过了健康儿童体表面积校正后的左心室最大厚度的第95百分位数(HCM的主要超声心动图标准)。然而,在27名G+儿童中的14名(52%)中发现了等容舒张时间延长、3DE上左心房容积增加或NT-proANP水平升高,所有这些特征都提示舒张功能障碍。
在携带HCM致病突变的儿童中,约一半病例存在舒张功能障碍的迹象,因为这些儿童中只有小部分存在LVH。